Sector News

AstraZeneca CEO, worried by Brexit, not signing UK government letter

September 11, 2017
Life sciences

AstraZeneca Chief Executive Pascal Soriot, fearing a potentially abrupt Brexit, said on Saturday that lack of progress in negotiations made it impossible for him to sign a public letter of support for the British government’s strategy.

As reported by Reuters this week, Prime Minister Theresa May’s office has asked companies listed in the blue-chip FTSE 100 index to put their name to a public letter welcoming the government’s efforts to make Brexit a success.

“The reason I didn’t sign is that I felt there are so many areas that are still uncertain. How can we support something that we don’t really understand fully?” Soriot told Reuters on the sidelines of a cancer conference in Madrid.

Executives at several companies have said privately that the request went down badly with many large corporations but they have been reluctant to comment publicly.

Soriot said his refusal to sign did not mean the drugmaker disagreed with Britain’s decision to leave the European Union, adding that it could have some positive aspects if it went hand-in-hand with increased support for the UK life sciences sector.

But the deep uncertainty about future terms of trade just 18 months before Brexit happens in March 2019 means exports of medicines could be hampered, he said.

“What is starting to worry me, I must say, is the potential for the one thing I didn’t think would happen which is a hard Brexit,” he said.

“If there is no extension we will be left in limbo because the UK will come out of Europe and we will have no trade agreements.”

Britain’s second-biggest pharmaceuticals company makes a large amount of products in the north of England, including the cancer drug Zoladex, sales of which are increasing rapidly in China and other countries around the world.

“We need to know that is not going to be disrupted because right now we are exporting under a trade agreement between the EU and China,” Soriot said.

Many companies fear that Britain’s move to leave the world’s largest trading bloc will increase bureaucracy, drive up costs and eat into profitability.

The public letter, which May’s advisers wanted Soriot and other business leaders to sign, states that signatories are confident that “global Britain has the potential to become one of the most productive economies of the 21st century”.

By Ben Hirschler

Source: Reuters

Related News

October 24, 2020

Neutralising the gluten threat: are we on the cusp of a coeliac disease breakthrough?

Life sciences

Coeliac disease causes long-term damage to patients’ small intestine and puts them at risk of other medical conditions. Treatment options are urgently needed. Allie Nawrat explores the promise of larazotide, the drug in development currently leading the pack.

October 24, 2020

Bone Therapeutics showcases allogeneic cell therapy data

Life sciences

Bone Therapeutics has announced positive 24-month follow-up results from its phase IIa study of Allob, its allogeneic cell therapy, in patients undergoing lumbar spinal fusion procedures.

October 24, 2020

UCB acquires new campus to support UK operations

Life sciences

Belgian pharma company UCB has agreed to acquire a new campus to further support its operations in the UK.

Send this to a friend